Andere talen Cognition Therapeutics, Inc.

Aandelen

CGTX

US19243B1026

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,98 ^USD	+1,54%		+2,59%	+7,03%

29/04	Cognition Therapeutics, Inc. Voltooit de inclusie in de Fase 2 SHIMMER studie van CT1812 in milde tot matige dementie met Lewy lichaampjes	CI
12/04	Transcript : Cognition Therapeutics, Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics, Inc. Completes Enrollment in Phase 2 SHIMmer Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies	29/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer's disease	23/04
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease	22/04
Cognition Therapeutics to Present at the Needham Virtual Healthcare Conference	02/04
Cognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024	01/04
Cognition Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Cognition Therapeutics Reports Year End 2023 Financial Results and Provides Business Update	26/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results	15/03
Cognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common Stock	14/03
Cognition Therapeutics Prices $11.5 Million Stock Offering	12/03
Cognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock	12/03
Cognition Therapeutics Starts Public Offering; Shares Decline	11/03
Cognition Therapeutics : Results of Operations and Financial Condition - Form 8-K	11/03
Cognition Therapeutics, Inc. Provides Consolidated Earnings Guidance for the Year Ended December 31, 2023	11/03
Cognition Therapeutics Announces Proposed Public Offering of Common Stock	11/03
Cognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease Studies	06/03
Cognition Therapeutics, Inc. Presents Analyses at AD/PD 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer?s Disease Studies	06/03
Cognition Therapeutics to Present at the TD Cowen Health Care Conference	26/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Cognition Therapeutics, Inc.

Aandelen

CGTX

US19243B1026

Andere talen

Filters